Shionogi has agreed to buy all of IntraBio, a Texas-based developer of rare neurological drugs, for $2bn (¥315.56bn at the notice's rate of ¥157.78 to the dollar). The board approved the deal and the contract was signed on 5 October 2026, according to Shionogi's disclosure that day. The purchase is made through its US group company, Shionogi Inc., based in New Jersey.
What Shionogi gets
The deal gives Shionogi all rights worldwide to AQNEURSA (levacetylleucine) and related compounds, including intellectual property and sales rights. Shionogi says AQNEURSA is approved in the US and Europe for the neurological symptoms of Niemann-Pick disease type C, and is on sale in the US. Shionogi describes the disease as a hereditary, progressive neurodegenerative disorder affecting roughly one person in 100,000.
A second indication is more recent. On 18 September 2026 the US Food and Drug Administration approved AQNEURSA for ataxia-telangiectasia, which Shionogi calls the first treatment approved for that condition. The company says it is also the only one currently approved. A filing to add the indication in Europe has been made, but the notice gives no decision date. Shionogi cites estimates that the disease affects between 1 in 40,000 and 1 in 100,000 people.
The commercial logic
Shionogi has been building a rare-disease business outside its core infectious-disease franchise. Since April 2026 it has sold edaravone, its treatment for amyotrophic lateral sclerosis, globally, marketed in the US as RADICAVA. Once the deal closes, Shionogi says it will use that US platform to bring AQNEURSA to patients. It also expects to absorb IntraBio's people and know-how, which it says will speed work on its own rare-disease candidates for Fragile X syndrome, Jordan syndrome and Pompe disease, along with earlier research candidates. Those are Shionogi's stated aims, and the notice makes no claim about the clinical prospects of those programmes.
What the target looks like
IntraBio, founded in 2015 and led by President and CEO Mallory Factor, is only now generating meaningful revenue. Its sales were zero in 2023, $3.535mn in 2024 and $67.867mn in 2025, on US accounting standards. It has not made an operating profit in any of the three years. Net income of $78.283mn in 2024 sits between two net losses, and the notice does not explain it. Net assets at the end of 2025 were $144.549mn.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Sales | 0 | 3.535 | 67.867 |
| Operating profit (loss) | (22.434) | (56.215) | (35.292) |
| Net profit (loss) | (26.827) | 78.283 | (35.371) |
| Net assets | 35.411 | 135.344 | 144.549 |
The $2bn price therefore compares with net assets of $144.549mn and 2025 sales of $67.867mn. Shionogi calls the purchase a strategic investment in new rare-disease products and expertise.
Conditions and timing
Completion is expected in November or December 2026. It depends on the expiry of all applicable competition-law waiting periods and on regulatory approvals and clearances in the relevant jurisdictions. After closing, Shionogi Inc. will hold 100% of IntraBio's voting rights, from zero today.
Shionogi says it is still assessing the effect on its consolidated results for the year to March 2027 and will disclose anything further promptly. The notice does not say how the payment will be funded. IntraBio's selling shareholders, described only as individuals, trusts and corporations, are undisclosed at their request and for privacy reasons, and IntraBio's shareholder structure is withheld at its wish. Shionogi reports no capital, personnel or business ties with IntraBio.
Goldman Sachs advised Shionogi financially and Cleary Gottlieb Steen & Hamilton advised it on legal matters. IntraBio used Centerview Partners and Morgan Stanley for finance, with Kirkland & Ellis and DLA Piper as legal counsel.